NCT01044329Unknown2 期
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Visual acuity
研究概览
简要总结
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Recent onset (less than 3 months) BRVO
排除标准
- •Any previous intervention
研究组 & 干预措施
Intravitreal bevacizumab
Active Comparator
干预措施: Bevacizumab (Drug)
Intravitreal triamcinolone
Active Comparator
干预措施: Triamcinolone Acetonide (Drug)
结局指标
主要结局
Visual acuity
时间窗: 6 months
次要结局
- central macular thickness(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)Central Retinal Vein OcclusionNCT01178697Shahid Beheshti University of Medical Sciences
终止
3 期
Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular OedemaUveitisNCT01095809Hospital Clinic of Barcelona5
已完成
3 期
Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular EdemaDiabetic Macular EdemaNCT01823081Shahid Beheshti University of Medical Sciences74
终止
3 期
A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROPRetinopathy of PrematurityNCT04634604Jaeb Center for Health Research16
撤回
3 期
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)Age Related Macular DegenerationNCT00557791OPKO Health, Inc.